ACHN


Stock Update (NASDAQ:ACHN): Achillion Pharmaceuticals, Inc. Presents Interim Phase 1 Results for ACH-4471

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) presented interim results from a phase 1 study with its novel small molecule factor D inhibitor, ACH-4471, at the 21st …

Baird’s Focus Ideas: Gilead Sciences, Inc. (GILD), Achillion Pharmaceuticals, Inc. (ACHN)

With summer approaching, most of the major brokerage firms are making some changes and additions to their firms top stock ideas. At one of …

Company Update (NASDAQ:ACHN): Achillion Pharmaceuticals, Inc. Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced the initiation of a phase 1 study with ACH-4471, the Company’s first orally-administered, highly potent and specific small molecule …

Company Update (NASDAQ:ACHN): Achillion Pharmaceuticals, Inc. Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that a submitted abstract has been accepted for oral presentation at the 57th Annual Meeting of the American Society …

Stock Update (NASDAQ:ACHN): Achillion Pharmaceuticals, Inc. Reports 100% SVR12 From Second Cohort of Patients in the Previously-Completed Six Week Phase 2 Trial

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced additional interim results from a Phase 2 study evaluating odalasvir (also known as ACH-3102), a NS5A inhibitor, in combination …

Tuesday’s Top Upgrades: Bank of America Corp (BAC), Amgen, Inc. (AMGN), Regeneron Pharmaceuticals Inc (REGN), Achillion Pharmaceuticals, Inc. (ACHN)

A number of Wall Street analysts weighed in on their favorite stocks this morning before market open. Below are the most notable analyst …